Saadet ARSLAN, İlter VARİNLİ, Merih SOYLU

Comparison of life quality scores of ranibizumab-treated patients with age-related macular degeneration

Amaç: Eksudatif tip yaşa bağlı makula dejenerasyonu saptanan ve intravitreal Ranibizumab enjeksiyonu yapılan hastalarda görme keskinlikleri, floresein anjiyografi, optik koherens tomografi ve yaşam kalitesi değişimini değerlendirmek. Gereç ve Yöntem: Bu çalışma eksudatif tip yaşa bağlı makula dejenerasyonu olan ve ranibizumab enjeksiyonu yapılan 48 hastayı içermektedir. Bu çalışmada hastaların demografik özellikleri, enjeksiyon öncesi ve sonrası düzeltilmiş görme keskinlikleri, anjiyografi, optik koherens tomografi değişiklikleri ve yaşam kalitesi anketi skorları prospektif olarak değerlendirildi. Bulgular: Hastalar ortalama 20±1 ay süreyle takip edildi. Ranibizumab enjeksiyonu sonrası görme keskinliğinde, 3 sıra ve üzerinde kazanımı olan 12 hasta (%25), 3 sıradan az kazanımı olan 28 hasta (%58.3), 3 sıradan az kaybı olan 6 hasta (%12.5) ve 3 sıradan fazla kaybı olan 2 hasta (%4.2)'dır. Yüksek tansiyon ve aile hikayesi pozitif olan hastalarda Çalışmasındaki artış daha düşük oldu. Bu çalışmada, ranibizumab enjeksiyonu sonrası görme keskinliği artan hastalarda Ulusal Göz Enstitüsü Görsel Fonksiyon Anketi yaşam kalitesi değerlerinin arttığı tespit edildi ve bu fark istatistiksel olarak anlamlı bulundu. Sonuç: İntravitreal ranibizumab enjeksiyonu ile tedavi edilen eksudatif tip yaşa bağlı makula dejenerasyonlu olguların görme keskinliğinde artış saptandı. Yaşa bağlı makula dejenerasyonu olan hastalarda Ulusal Göz Enstitüsü Görsel Fonksiyon Anketi güvenilir sonuçlar verdi ve işlem sonrası ankette puan artışı saptandı.

Ranibizumab uygulanan yaşa bağlı makula dejenerasyonlu hastalarda yaşam kalitesi skorlarının karşılaştırılması

Purpose: To evaluate the visual acuity, fluorescein angiography, optic coherence tomography and life quality of patients diagnosed with exudative age-related macular degeneration and administered with intravitreal Ranibizumab injection. Material and Methods: This study included of 48 different patients who were diagnosed as exudative agerelated macular degeneration and administered with ranibizumab injection. In this study, demographic characteristics, pre- and post-injection corrected visual acuity, angiography, optic coherence tomography alteration and the scores of quality of life questionnaire were prospectively analyzed. Results: The patients were followed up for 20±1 months on average. After ranibizumab injection, 12 patients (25%) gained >=3 lines of visual acuity, 28 patients (58.3%) gained

PDF

___

Lin RC, Rosenfeld PJ. Antiangiogenic therapy in neovascular age-related macular degeneration. Int Ophthalmol Clin. 2007;47:117-37.
Emerson MV, Andreas KL. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008;2:377-88.
Klein R, Klein BE, Knudtson MD, Wong TY. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi ethnic study of atherosclerosis. Ophthalmology. 2006;113:373-80.
Parmeggiani F, Romano MR, Costagliola C, Semeraro F, Incorvaia C, D'Angelo S et al. Mechanism of inflammation in age-related macular degeneration. Mediators Inflamm. 2012;546786.
Rosenfeld PJ, Schwartz SD, Blumenkranz MS. Maximum tolerated dose of a humanized anti- vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology. 2005;112:1048-53.
Toprak AB, Eser E, Guler C. Cross-validation of the Turkish Version of The 25-Item National Eye Institute Functioning Questionnaire. Ophthalmolic Epidemiol. 2005;12:259-69.
Mangione CM, Berry S, Spritzer K. Identifying the content area for the 51-item National Eye Institute Visual Function Questionnaire: results from focus groups with visually impaired persons. Arch Ophthalmol. 1998;116:227-33.
Clemons TE, Chew EY, Bressler SB, McBee W. Age-related eye disease study research group national eye institute visual function questionnaire (AREDS): AREDS Report No 10. Arch Ophthalmol. 2003;121:211-17.
Orr P, Rentz AM, Margolis MK. Validation of the national eye institute visual function questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:3354-59.
Suñer IJ, Kokame GT, Yu E, Ward J, Dolan C, Bressler NM. Responsiveness of NEI VFQ-25 to changes in visual acuity in neovascular AMD: validation studies from two phase 3 clinical trials. Invest Ophthalmol Vis Sci. 2009;50:3629-35.
Mangione CM, Lee PP, Gutierrez PR. National Eye Institute Visual Function Questionnaire Field Test Investigators. Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol. 2001;119:1050-58.
Klein R, Cruickshanks KJ, Nash SD, Krantz EM, Nieto FJ, Huang GH et al. The prevalence of age- related macular degeneration and associated risk factors. Arch Ophthalmol. 2010;128:750-58.
Klein R, Klein BE, Knudston MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration. The Beaver Dam Eye Study. Ophthalmology. 2007;114:253-62.
Seddon JM, Chen CA. The epidemiology of age- related macular degeneration. Int Ophthalmol Clin. 2004;44:17-39.
Klein R, Klein BE, Tomany SC, Moss SE. Ten-year incidence of age-related maculopathy and smoking and drinking: the beaver dam eye study. Am J Epidemiol. 2002;156:589-98.
Thornton J, Edwards R, Mitchell P, Harrison RA, Buchan I, Kelly SP. Smoking and age-related macular degeneration: a review of association. Eye Sci. 2005;19:935-44.
Hyman L, Schachat AP, He Q, Leske MC. Hypertension, cardiovascular disease and age-related macular degeneration. Age-related macular degeneration risk factors study group. Arch Ophthalmol. 2000;118:351-58.
Tan JS, Mitchell P, Smith W, Wang JJ. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration: the blue mountains eye study (BMES). Ophthalmology. 2007;114:1143-50.
Assink JJ, Klaver CC, Houwing-Duistermaat JJ, Wolfs RC, Van Duijn CM, Hofman A et al. Heterogeneity of the genetic risk in age-related macular disease: a population-based familial risk study. Ophthalmology. 2005;112:482-87.
Chen Y, Bedell M, Zhang K. Age-related macular degeneration: genetic and environmental factors of disease. Mol Interv. 2010;10:271-81.
Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chunq CY et al. Ranibizumab for neovascular age-related macular degeneration. N England J Med. 2006;355:1419-31.
Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-44.
Iyigun E, Bayer A. Validity and reliability study for the NEI-VFO-39 scale in chronic ophthalmic diseases. PMID: 20346083. 2009.
Rakic JM, Leys A, Brié H, Denhaerynck K, Pacheco C, Vancayzeele S et al. Real-world variability in ranibizumab treatment and associated clinical, quality of life and safety outcomes over two years in patients with neovascular age-related macular degeneration. Clin Ophthalmol. 2013;7:1849-58.
Orr P, Rentz AM, Margolis MK. Validation of the national eye institute visual function questionnaire-25 (NEI VFQ-25) in age-related macular degeneration. Invest Ophthalmol Vis Sci. 2011;52:3354-9.